European Survey on Adult People With Type 1 Diabetes and Their Caregivers: Insights Into Perceptions of Technology.
Europe
device
experience
insulin
perception
type 1 diabetes
Journal
Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
medline:
8
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
aheadofprint
Résumé
Type 1 diabetes (T1D) is a complex condition requiring constant monitoring and self-management. The landscape of diabetes management is evolving with the development of new technologies. This survey aimed to gain insight into the perceptions and experiences of people with T1D (PWD) and their caregivers on the use of technology in diabetes care, and identify future needs for T1D management. PWD and caregivers (≥18 years) living in five European countries (France, Germany, Italy, Spain, and the United Kingdom) completed an online survey. Data were collected during July and August 2021. Responders included 458 PWD and 54 caregivers. More than 60% of PWD perceived devices/digital tools for diabetes management as useful and 63% reported that access to monitoring device data made their life easier. Nearly half of participants hoped for new devices and/or digital tools. While approximately one-third of all PWD had used teleconsultation, perceptions and usage varied significantly between countries and by age (both Most PWD and caregivers had positive perceptions and experiences of new technologies/digital solutions for diabetes management, although improved support and structured education for devices/digital tools are still required.
Sections du résumé
BACKGROUND
UNASSIGNED
Type 1 diabetes (T1D) is a complex condition requiring constant monitoring and self-management. The landscape of diabetes management is evolving with the development of new technologies. This survey aimed to gain insight into the perceptions and experiences of people with T1D (PWD) and their caregivers on the use of technology in diabetes care, and identify future needs for T1D management.
METHODS
UNASSIGNED
PWD and caregivers (≥18 years) living in five European countries (France, Germany, Italy, Spain, and the United Kingdom) completed an online survey. Data were collected during July and August 2021.
RESULTS
UNASSIGNED
Responders included 458 PWD and 54 caregivers. More than 60% of PWD perceived devices/digital tools for diabetes management as useful and 63% reported that access to monitoring device data made their life easier. Nearly half of participants hoped for new devices and/or digital tools. While approximately one-third of all PWD had used teleconsultation, perceptions and usage varied significantly between countries and by age (both
CONCLUSIONS
UNASSIGNED
Most PWD and caregivers had positive perceptions and experiences of new technologies/digital solutions for diabetes management, although improved support and structured education for devices/digital tools are still required.
Identifiants
pubmed: 37937589
doi: 10.1177/19322968231208690
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19322968231208690Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Alfred Penfornis: Advisory panel member for AstraZeneca, MSD, and Novo Nordisk, and speaker for Abbott, Amgen, Bayer MSD, Sanofi, Novo Nordisk, Eli Lilly, and Medtronic. Su Down: Funding from the following companies for providing educational sessions and documents, and advisory boards: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, MSD, Mylan, Napp, Novo Nordisk, Roche, Sanofi, and Viatris. Antoine Seignez: Employee of Carenity, providing consultancy to Sanofi. Alizé Vives: Employee of Carenity, providing consultancy to Sanofi. Mireille Bonnemaire: Employee of Sanofi, holds stocks/shares in Sanofi. Bernhard Kulzer: Speaker’s honoraria and/or advisory boards and/or research grants from Abbott, Ascensia, Bayer, Becton Dickinson, Berlin Chemie, Dexcom, Insulet, Novo Nordisk, Roche, and Sanofi.